Search

Displaying results 2071 - 2080 of 8412 in total
  1. Drug

    Felbamate

    go.drugbank.com/drugs/DB00949
    Approved

    Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  2. Drug

    PF-05180999

    go.drugbank.com/drugs/DB14885
    Investigational

    PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999).

  3. Drug

    PF-04937319

    go.drugbank.com/drugs/DB15009
    Investigational

    PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).

  4. Drug

    PF-06291874

    go.drugbank.com/drugs/DB15065
    Investigational

    PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes

  5. Drug

    PF-06882961

    go.drugbank.com/drugs/DB16043
    Investigational

    PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).

  6. Drug

    Belladonna

    go.drugbank.com/drugs/DB13913
    Approved

    [DB00572] is a non-selective muscarinic antagonist that is mainly used as an adjunct for anaesthesia.

    Mixtures: Cafergot Pb Tab, Cafergot Pb SupProducts: HE WEI PILL
  7. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. … Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B.

  8. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262076] It may be inherited (congenital TTP; cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of all cases of TTP. … [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.

  9. Drug

    Tolvaptan

    go.drugbank.com/drugs/DB06212
    ApprovedInvestigational

    Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  10. Drug

    Varenicline

    go.drugbank.com/drugs/DB01273
    ApprovedInvestigational

    Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015.